Altimmune, Inc. (NASDAQ:ALT)
| Market Cap | $258.80M-72.3% |
| Revenue (ttm) | $26.00K+30.0% |
| Net Income | -$104.35M-24.4% |
| EPS | -$0.72+32.7% |
| Shares Out | 194.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Feb 6, 2017 |
| Volume | 4,019,048 |
| Open | $1.39 |
| Previous Close | $1.41 |
| Day's Range | $1.32 - $1.46 |
| 52-Week Range | $1.32 - $6.44 |
| Beta | 0.18 |
| Analysts | Buy |
| Price Target | $10.00(+651.88%) |
| Earnings Date | Mar 4, 2027 |
About ALT
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Altimmune, Inc. Stock Analysis — InsiderScore
Altimmune, Inc. scored higher than 37% of companies evaluated by InsiderBuying, and ranked 50th out of 103 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Altimmune, Inc. bought $82.2K of stock across 3 purchases in the last 90 days, the largest of them $49.7K.
The average purchase added about 28% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating ALT in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 4, 2027Earnings report
$ALT stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ALT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ALT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ALT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ALT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ALT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ALT
| VTIVanguard Morningstar Total Stock Market ETF | $9.24M |
| IWMiShares Russell 2000 ETF | $7.04M |
| XBIState Street SPDR S&P Biotech ETF | $6.43M |
| VXFVanguard Extended Market ETF | $3.86M |
| IWNiShares Russell 2000 Value ETF | $2.51M |
| VTWOVanguard Russell 2000 ETF | $2.31M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ALT’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 earnings miss with funding concerns offset by analyst support and positive clinical data publication in MASH program.
Recent Insider Activity
Insider Score Trend Over Time
+0.8 since Nov 14Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| BBC | Virtus Biotech Clinical Trials ETF | 0.55% |
| PEPT | REX Peptide ETF | 0.42% |
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.35% |
| SBIO | ALPS Medical Breakthroughs ETF | 0.20% |
| IWC | iShares Micro-Cap ETF | 0.09% |
| XBI | State Street SPDR S&P Biotech ETF | 0.07% |
| FESM | Fidelity Enhanced Small Cap ETF | 0.04% |
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 0.03% |
| IBB | iShares Biotechnology ETF | 0.02% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.02% |
| PWS | Pacer WealthShield ETF | 0.02% |
| LABU | Direxion Daily S&P Biotech Bull 3X Shares | 0.02% |
Weight is the stock’s share of each fund’s holdings.
